The unmet need in DLBCL
Are we ready for mutational directed treatment: addressing the genomic basis of myeloma
Gareth Morgan et al.
The discovery and role of BCL2 and microRNA in CLL
The multi-cohort SCHOLAR-1 study of refractory aggressive DLBCL
iwNHL 2016 highlights: CAR T-cell therapy, DLBCL and new technologies